CryoVaxTM is an in-situ, personalized, anti-cancer vaccine which combines a percutaneous, image-guided, cryoablation of a selected tumor lesion with the intralesional injection of AlloStim®. The cryoablation kills tumor cells using extreme cold. The freezing of tumors releases endogenous chaperone proteins (a/k/a heat shock proteins) into the surrounding microenvironment as a source of tumor antigen. The intralesional injection of AlloStim® serves as an adjuvant to drive tumor-specific Th1 immunity.




Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more